Tags

Type your tag names separated by a space and hit enter

[Rimonabant improves cardiometabolic risk profile in obese or overweight subjects: overview of RIO studies].
Rev Med Suisse. 2006 Aug 23; 2(76):1916-23.RM

Abstract

RIO (Rimonabant In Obesity and related disorders) is a large phase 3 programme (>6600 patients) evaluating the efficacy and safety of rimonabant (5 or 20 mg/day), a CBI receptor antagonist of endocannabinoid system, in obese or overweight patients with or without comorbidities (RIO-Europe and RIO-North America), with untreated dyslipidaemia (RIO-Lipids) or with type 2 diabetes treated with metformin or sulfonylurea (RIO-Diabetes). Compared to placebo, rimonabant 20 mg/day consistently increases weight loss, reduces waist circumference, increases HDL cholesterol, lowers triglyceride levels, diminishes insulin resistance, and reduces the prevalence of metabolic syndrome. Almost half of the metabolic effects, including adiponectin increase, occur beyond weight loss, suggesting a direct peripheral effect of rimonabant.

Authors+Show Affiliations

Université de Liège, Service de diabétologie, nutrition et maladies métaboliques, CHU Sart Tilman, Liège, Belgique. andre.scheen@chu.ulg.ac.beNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

fre

PubMed ID

16972542

Citation

Scheen, A J., et al. "[Rimonabant Improves Cardiometabolic Risk Profile in Obese or Overweight Subjects: Overview of RIO Studies]." Revue Medicale Suisse, vol. 2, no. 76, 2006, pp. 1916-23.
Scheen AJ, Van Gaal LG, Després JP, et al. [Rimonabant improves cardiometabolic risk profile in obese or overweight subjects: overview of RIO studies]. Rev Med Suisse. 2006;2(76):1916-23.
Scheen, A. J., Van Gaal, L. G., Després, J. P., Pi-Sunyer, X., Golay, A., & Hanotin, C. (2006). [Rimonabant improves cardiometabolic risk profile in obese or overweight subjects: overview of RIO studies]. Revue Medicale Suisse, 2(76), 1916-23.
Scheen AJ, et al. [Rimonabant Improves Cardiometabolic Risk Profile in Obese or Overweight Subjects: Overview of RIO Studies]. Rev Med Suisse. 2006 Aug 23;2(76):1916-23. PubMed PMID: 16972542.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Rimonabant improves cardiometabolic risk profile in obese or overweight subjects: overview of RIO studies]. AU - Scheen,A J, AU - Van Gaal,L G, AU - Després,J P, AU - Pi-Sunyer,X, AU - Golay,A, AU - Hanotin,C, PY - 2006/9/16/pubmed PY - 2006/11/11/medline PY - 2006/9/16/entrez SP - 1916 EP - 23 JF - Revue medicale suisse JO - Rev Med Suisse VL - 2 IS - 76 N2 - RIO (Rimonabant In Obesity and related disorders) is a large phase 3 programme (>6600 patients) evaluating the efficacy and safety of rimonabant (5 or 20 mg/day), a CBI receptor antagonist of endocannabinoid system, in obese or overweight patients with or without comorbidities (RIO-Europe and RIO-North America), with untreated dyslipidaemia (RIO-Lipids) or with type 2 diabetes treated with metformin or sulfonylurea (RIO-Diabetes). Compared to placebo, rimonabant 20 mg/day consistently increases weight loss, reduces waist circumference, increases HDL cholesterol, lowers triglyceride levels, diminishes insulin resistance, and reduces the prevalence of metabolic syndrome. Almost half of the metabolic effects, including adiponectin increase, occur beyond weight loss, suggesting a direct peripheral effect of rimonabant. SN - 1660-9379 UR - https://www.unboundmedicine.com/medline/citation/16972542/[Rimonabant_improves_cardiometabolic_risk_profile_in_obese_or_overweight_subjects:_overview_of_RIO_studies]_ L2 - https://medlineplus.gov/metabolicsyndrome.html DB - PRIME DP - Unbound Medicine ER -